Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
19 Outubro 2023 - 9:03AM
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company")
(Nasdaq: CPRX), a commercial-stage biopharmaceutical company
focused on in-licensing, developing, and commercializing novel
medicines for patients living with rare diseases, today announced
the appointment of Richard J. Daly as its new Chief Executive
Officer ("CEO") effective January 1, 2024. Mr. Daly is a seasoned
pharmaceutical executive bringing more than three decades of
experience to Catalyst. In order to facilitate an orderly
transition, Patrick J. McEnany, Founder, Chairman, and CEO, will
retire from the CEO position effective December 31, 2023, and at
that time will continue in his role as Chairman of the Board.
"Today's announcement paves the way for a
seamless transition for the new CEO at Catalyst. Rich brings a
wealth of industry experience, particularly on the commercial side,
along with a profound understanding of our business, strategy,
team, and culture. His proven track record and deep knowledge of
our Company make him the ideal leader to guide Catalyst toward the
next level of success. I eagerly anticipate collaborating with Rich
to ensure a smooth transition in this important leadership role,"
said Patrick J. McEnany, Chairman and CEO of Catalyst. "Our Board
of Directors have been engaged in a very thoughtful, ongoing CEO
succession planning and has conducted a rigorous national search
with a highly regarded executive search firm. While we
identified many highly qualified candidates, at the conclusion of
our interviews, our board of directors unanimously agreed that Rich
Daly, a member of our board for the past eight years, was the
best-suited candidate to be our next CEO."
"I am honored to serve as Catalyst's new CEO at
such a pivotal point in the Company's evolution," said Richard J.
Daly. "With a strong commitment to sustained execution across the
business, we will remain focused to further capitalize on our
compelling accomplishments. We are well-poised for a promising
future, and I look forward to advancing our objectives to deliver
on our growth strategy and initiatives."
Mr. Daly has held distinguished positions in
multinational corporations and at innovative biotech companies.
Prior to his appointment at Catalyst, Mr. Daly served as President
of CARsgen Therapeutics Corporation since January 2022. Previously,
he served as Chief Operating Officer at Beyond Springs Inc. from
2018 to 2022 and as CEO, President, and Chairman of Neuralstem,
Inc., a publicly held biotechnology company specializing in central
nervous system therapies based on neuronal stem cell technology
from 2016 to 2018.
Throughout his career, Mr. Daly has held
prominent leadership positions at leading global pharmaceutical
companies, including serving as President of AstraZeneca's U.S.
diabetes subsidiary, leading all commercial and medical plans and
objectives for a $1.2 billion revenue, 3,000-employee division, and
the successful launch of an orphan rare disorder drug, Myalept, for
the treatment of Lipodystrophy. Earlier, Mr. Daly served at Takeda
and TAP Pharmaceuticals, a joint venture established between Takeda
and Abbott Laboratories, where he held several senior leadership
positions, including the Executive Vice President at Takeda
Pharmaceutical North America and the Senior Vice President of
Marketing at TAP Pharmaceuticals.
Mr. Daly has served on Catalyst's Board of
Directors since February 2015 and will continue to serve on the
board as the newly appointed CEO. He holds an MBA from the Kellogg
School of Management at Northwestern University and a
Bachelor of Science in Microbiology from the University of
Notre Dame.
About Catalyst Pharmaceuticals
With exceptional patient focus, Catalyst is
committed to developing and commercializing innovative
first-in-class medicines that address rare neurological and
epileptic diseases. Catalyst's flagship U.S. commercial
product is FIRDAPSE® (amifampridine) Tablets 10 mg, approved
for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS") for
adults and for children ages six to seventeen. In January
2023, Catalyst acquired the U.S. commercial rights to
FYCOMPA® (perampanel) CIII, a prescription medicine approved
in people with epilepsy aged four and older alone or with other
medicines to treat partial-onset seizures with or without
secondarily generalized seizures and with other medicines to treat
primary generalized tonic-clonic seizures for people with epilepsy
aged 12 and older. Further, Canada's national healthcare
regulatory agency, Health Canada, has approved the use of
FIRDAPSE for the treatment of adult patients
in Canada with LEMS. Finally, on July 18, 2023,
Catalyst acquired an exclusive license for North
America for vamorolone, a promising best-in-class dissociative
anti-inflammatory steroid treatment for Duchenne Muscular
Dystrophy. Vamorolone has received FDA Orphan Drug and Fast
Track designations and has been granted a PDUFA action date
of October 26, 2023.
For more information, visit the Company's
website at www.catalystpharma.com. For Full
Prescribing and Safety Information for FIRDAPSE®, please
visit www.firdapse.com. For Full Prescribing Information,
including Boxed WARNING for FYCOMPA®, please
visit www.fycompa.com.
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for the fiscal year 2022 and its other
filings with the U.S. Securities and Exchange
Commission ("SEC"), could adversely affect Catalyst. Copies of
Catalyst's filings with the SEC are available from
the SEC, may be found on Catalyst's website, or may be
obtained upon request from Catalyst. Catalyst does not undertake
any obligation to update the information contained herein, which
speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.co
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024